Brigatinib NDA Granted Priority Review by FDA

Share this content:
The FDA has accepted for review the NDA for brigatinib as treatment for metastatic, ALK-positive non-small cell lung cancer.
The FDA has accepted for review the NDA for brigatinib as treatment for metastatic, ALK-positive non-small cell lung cancer.

The U.S. Food and Drug Administration has accepted for review the New Drug Application (NDA) for brigatinib as treatment for metastatic, ALK-positive non-small cell lung cancer (NSCLC) that progressed with crizotinib, and has granted ARIAD's request for Priority Review of the NDA.1

The NDA submission is based on data from a phase 1/2 trial and the pivotal phase 2 ALTA trial, which evaluated the activity and safety of brigatinib among patients with locally advanced or metastatic ALK-positive NSCLC previously treated with crizotinib.

Preliminary results of the ALTA study showed an objective response rate of 54% in patients who received brigatinib, with a median progression-free survival of 12.9 months.

The FDA is required to take action on the NDA by April 29, 2017, 6 months from the filing of the application, rather than the 10 months required under standard review.

RELATED: Adding Pembrolizumab to Chemo Improves Efficacy in Metastatic NSCLC

Brigatinib has also previously received Breakthrough Therapy designation from the FDA for the treatment of patients with ALK-positive NSCLC whose tumors are resistant to crizotinib, and was granted orphan drug designation for ALK-positive, ROS1-positive, and EGFR-positive NSCLC.           

Reference

  1. ARIAD announces U.S. Food and Drug Administration acceptance of NDA filing for brigatinib. ARIAD website. http://investor.ariad.com/phoenix.zhtml?c=118422&p=RssLanding&cat=news&id=2217368. Updated October 31, 2016. Accessed November 1, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs